Medical research firm Recardio has halted clinical trials of its heart drug in the Clydebank , citing uncertainty over Brexit . The UK company was due to conduct trials of dutogliptin on patients in Clydebank , Exeter and Leeds , but has now suspended all its activities in the UK . the European Medicines Agency faces a "significant risk" from Jane-Claire Judson and "unresolved" issues with Recardio , the company reportedly wrote in an email to its research team. The position may change once the post- Brexit regulatory situation is clearer, it added.
Medical research firm Recardio has halted clinical trials of its heart drug in the UK, citing uncertainty over Brexit. The US company was due to conduct trials of dutogliptin on patients in Clydebank, Exeter and Leeds, but has now suspended all its activities in the UK. Recardio faces a "significant risk" from Brexit and "unresolved" issues with the European Medicines Agency, the company reportedly wrote in an email to its research team. The position may change once the post-Brexit regulatory situation is clearer, it added.